Meglitinide analogues are a new family of nonsulfonylurea insulin secretagogues that stimulate AIM: To assess the effect of miglitol versus repaglinide on postprandial hyperglycemia and glycosylated hemoglobin in Type-2 diabetes mellitus.
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shown that postprandial hyperglycemia may be a more accurate predictor of HbA 1C mortality than fasting hyperglycemia. [2] [3] [4] information has focussed attention on postmeal
Currently two oral group of drugs i.e. alpha glucosidase inhibitors and meglitinide analogs (nonsulfonylurea secretagogues) are available that specifically target postprandial hyperglycemia. Alpha glucosidase inhibitors are being widely used in the treatment of type-2 diabetes. They delay the absorption of carbohydrates from small intestine and thus have a lowering effect on postprandial blood glucose and insulin levels. [5] Miglitol is the first pseudomonosaccharide alpha glucosidase inhibitor which has similar efficacy to acarbose even at lower therapeutic doses and additionally has the advantage of being non hepatotoxic. [6] Miglitol is a useful first line agent for treatment of Type-2 diabetes patients who are insufficiently controlled by diet alone and has been approved for monotherapy as well as combination with other antidiabetic drugs.
Introduction
Diabetes mellitus is the single most important metabolic disease recognized worldwide as one of the leading causes of death and disability. [1] Recent studies have insulin release by inhibiting ATP sensitive potassium channels of the β-cell membrane via binding to a receptor distinct from that of sulfonylureas. Meglitinide analogues have a rapid onset and shorter duration of action; as a result insulin secretion is stimulated to a greater extent within the first few minutes of their administration, hence they are effective in controlling postprandial surge of blood glucose levels.
[8]
Repaglinide is a meglitinide analogue more efficacious than nateglinide and has been approved for monotherapy as well as in combination with other antidiabetic agents for the treatment of Type-2 diabetes mellitus. Studies carried out by Drent et al [11] and Chiasson et al. [12] reported that treatment with miglitol in Type-2 diabetes patients produced a significant reduction in blood glucose level and HbA 1C . Studies carried out by Jovanovic et al [13] and Goldberg et al [14] reported that treatment with repaglinide in Type-2 diabetes produces a significant reduction in blood glucose level and HbA 1C .
Repaglinide has shown equal efficacy to pioglitazone, glimepiride, glibenclamide and metformin. [15] [16] [17] [18] But the studies comparing miglitol with repaglinide are limited and no clinical studies comparing repaglinide and prior to the start of study. 60 subjects were enrolled in the study after satisfying the inclusion and exclusion criteria. Included patients were explained in detail about the study pattern and related hazards. Those included went under all baseline investigations like complete blood count, liver function tests, kidney function tests, blood sugar level and glycosylated Hb, at the start of the study and at the end of the study. Enrolled patients were divided into two groups of thirty each by computer generated randomization chart (calculated from True Epistat, Standard version 1999). Group-1 patients received Tab. Miglitol 25 mg T.D.S with first bite of major miglitol in a head to head comparison have been reported. meals for duration of four weeks and 50 mg T.D.S with With the above background and the clinical data first bite of major meals for another twelve weeks. Group available to date, the present study was planned to 2 patients received Tab Repaglinide 0.5 mg T.D.S fifteen compare and evaluate, head to head the effect of miglitol minutes before each major meal for a period of four weeks versus repaglinide on postprandial blood sugar level and followed by 1 mg T.D.S fifteen min before each major glycosylated hemoglobin (HbA 1C ) in patients of Type-2 meal for a period of another 12 weeks. Each patient in respective group was provided free medications for fifteen days and was asked to visit the diabetic clinic for follow up and for collection of drugs. At each follow-up visit, patients were assessed for glycemic control (blood This study was randomized, parallel group, comparative, glucose level); history pertaining to adverse drug effect prospective study in patients of Type-2 diabetes mellitus.
was asked. All patients were given advice about diet and Sixty patients (n = 60) with uncontrolled blood glucose exercise. The study population was not allowed to take levels, defined as postprandial plasma glucose levels other antidiabetic drugs during the study period. more than 200 mg % and glycosylated haemoglobin more than 7% at visit one were included in the study provided
The primary efficacy measures for the study were change they were ready to give written informed consent and in postprandial blood glucose level from baseline to end had a history of Type-2 diabetes mellitus for six months of study (16 weeks) and change in glycosylated or longer, not controlled by dietary measures and hemoglobin (HbA 1C ) from baseline to end of study. The exercise. The exclusion criteria for patients were presence secondary efficacy measure was change in fasting blood of type 1 diabetes or requirement of insulin for diabetic glucose from baseline to end of study. For comparing the control, known allergy to study drugs, deranged liver effect of miglitol and repaglinide on blood sugar level function tests or kidney function tests, patients with and HbA before and after therapy paired 't' test was 1C history of myocardial infarction or anaemia, pregnant carried out. For comparison among groups unpaired 't' and lactating females, unwillingness to give written test was carried out. informed consent, history of antidiabetic medication diabetes mellitus.
Methodology
during the past three months, presence of gastrointestinal diseases like inflammatory bowel disease, large hernias, intestinal obstruction, active ulcers, chronic pancreatitis and patients taking any other concomitant medication effecting glucose homoeostasis like corticosteroids. Approval of the institutional ethics committee was taken
Results
Sixty patients (n=60) of Type-2 diabetes completed the study [ Table 1 ]. The mean post treatment glycosylated hemoglobin value decreased statistically in miglitol group (9.25 ± 1.96 to 8.1 ± 1.3, P < 0.001). Similarly the five patients (16.66%). As where the most common adverse effect in repaglinide group were nausea and headache in three patients (10 %) and dizziness in two patients (6.66%).
Group I: Miglitol, Group II: Repaglinide, n: number of patients Discussion mean post-treatment value for HbA 1C in repaglinide group also decreased statistically (9.74 ± 0.98 to 7.37 ± Diabetes is characterized by a high incidence of 0.79, P < 0.001). The mean postprandial plasma glucose cardiovascular disease and related complications. [19] levels were significantly reduced when compared to Poor control of hyperglycemia appears to play a baseline values in both the groups, miglitol (260.96 ± significant role in the development of these complications 75.41 mg/dl to 162.46 ± 27.97 mg/dl, P < 0.001) and in diabetes. [20] Recently, there has been increasing repaglinide (258.66 ± 47.92 mg/dl, P <0.001).
evidence that the postprandial state is an important contributing factor to the development of atherosclerosis When mean fasting plasma glucose values were compared and related complications. [21] after the therapy significant decrease was seen in miglitol postprandial phase is characterized by a rapid and large (138.53 ± 59.57 to 96.26 ± 18.77, P < 0.001) and repaglinide increase in blood glucose levels and these postprandial (148.30 ± 38.30 to 107.43 ± 38.26, P < 0.001) [ In diabetes, the repaglinide showed that mean reduction in glycosylated hemoglobin was more in repaglinide group (1.45 ± 1.20) as compared to miglitol (1.14 ± 1.20) but this value was not statistically significant (P = 0.32).
Similarly repaglinide also showed greater mean reduction in postprandial blood sugar level (101.2 ± 49.29 mg/dl) as compared to miglitol (88.5 ± 30.5 mg/dl) but this difference was not significant (P = 0.23).
However, the mean reduction for fasting plasma glucose level was more in miglitol group (45.6 ± 70.16 mg/dl) when compared to repaglinide (40.86 ± 26.36 mg/dl). This that tight glycemic control helps to prevent complications in Type-2 diabetes is also accumulating. [22, 23] Moreover, it appears that management of postprandial plasma glucose (PPG) levels, rather than fasting plasma glucose (FPG) levels, is important to prevent the complications associated with Type-2 diabetes. [3, 6] Unfortunately sulphonylureas and biguanides act principally to reduce fasting blood glucose levels. Postprandial blood sugar levels remain elevated in more than 60% of patients treated with these agents. [23] This has generated an interest for the search of agents which effectively reduce postprandial blood glucose levels. Tadvi
The present study demonstrated that miglitol and repaglinide are equally efficacious and significantly reduce the postprandial plasma blood sugar levels, fasting plasma blood sugar levels as well as glycosylated hemoglobin levels . In addition to the primary effect on postprandial glucose level alpha glucosidase inhibition by miglitol has several important secondary actions. This agent also decreases insulin resistance in peripheral tissues, which may in turn lead to a reduction in the to the postprandial blood glucose levels. [25] diabetes ) .
